35.Issue 09 september 22 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 09, Issue : 09, September – 2022

Title:

35.RECENT ADVANCEMENTS IN THE MANAGEMENT OF MULTI DRUG RESISTANT TUBERCULOSIS (MDR TB)
‬

Authors :

Mrs. Anila Kumari V S, Dr. Prasobh G R , Mrs. Sheeja Rekha A G, Mrs. Athira A S, Mrs. Seba M C, Mrs. Gini Jameena

Abstract :

Multidrug-resistant tuberculosis (MDR-TB) is an increasing global problem, with most cases arising from a blend of physician error and patient non-cooperation during treatment of susceptible TB. The extent and burden of MDR-TB varies significantly from country to country and region to region. There are many drugs available to treat tuberculosis like first line drugs and second line drugs. Even though the number of TB case is increasing day by day. This review is dealing with the FDA approved drugs and drugs under study.
Key Words: TB, MDR TB, First line drugs, Second line drugs, FDA approved drugs, drugs under study

Cite This Article:

Please cite this article in Anila Kumari V S et al, Recent Advancements In The Management Of Multi Drug Resistant Tuberculosis (MDR TB)., Indo Am. J. P. Sci, 2022; 09(9).

Number of Downloads : 10

References:

1. Nath, H. and S. Ryoo (2013). “First–and Second–Line Drugs and Drug Resistance.” Tuberculosis-Current Issues in Diagnosis and Management. InTech.
2. Sharma, S. K. and K. Dheda (2019). “What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?” Indian Journal of Medical Research 149(3): 309.
3. Jnawali, H. N. and S. Ryoo (2013). First–and second–line drugs and drug resistance. Tuberculosis-Current Issues in Diagnosis and Management, IntechOpen.
4. Lange, C., et al. (2014). Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement, Eur Respiratory Soc.
5. Ngwira, L.-G., et al. (2018). “Delay in seeking care for tuberculosis symptoms among adults newly diagnosed with HIV in rural Malawi.” The International Journal of Tuberculosis and Lung Disease 22(3): 280-286.
6. Lange, C., et al. (2018). “Revising the definition of extensively drug-resistant tuberculosis.” The Lancet Respiratory Medicine 6(12): 893-895.
7. Dye, C. (2006). “Global epidemiology of tuberculosis.” The Lancet 367(9514): 938-940.
8. Tiberi, S., et al. (2019). “Challenging MDR-TB clinical problems–The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs.” International Journal of Infectious Diseases 80: S68-S72.
9. McNeil, M. B., et al. (2018). “Cell wall inhibitors increase the accumulation of rifampicin in Mycobacterium tuberculosis.” BioRxiv: 424309.
10. Beavers, S. F., et al. (2018). “Tuberculosis mortality in the United States: epidemiology and prevention opportunities.” Annals of the American Thoracic Society 15(6): 683-692.
11. Mukonzo, J., et al. (2019). “Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals.” International Journal of Infectious Diseases 83: 98-101.
12. Pooran, A., et al. (2019). “Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation.” The Lancet Global Health 7(6): e798-e807.
13. Lei, B., et al. (2000). “Action mechanism of antitubercular isoniazid Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor.” Journal of Biological Chemistry 275(4): 2520-2526.
14. MacNeil, A., et al. (2019). “Global epidemiology of tuberculosis and progress toward achieving global targets—2017.” Morbidity and Mortality Weekly Report 68(11): 263.
15. Pawar, A., et al. (2019). “Ethambutol targets the glutamate racemase of Mycobacterium tuberculosis—an enzyme involved in peptidoglycan biosynthesis.” Applied microbiology and biotechnology 103(2): 843-851.
16. Speirs, R., et al. (1995). “Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.” Antimicrobial Agents and Chemotherapy 39(6): 1269-1271.
17. Dal Molin, M., et al. (2018). “Molecular mechanisms of intrinsic streptomycin resistance in Mycobacterium abscessus.” Antimicrobial Agents and Chemotherapy 62(1): e01427-01417.
18. Liu, T., et al. (2019). “New insights into the effect of pH on the mechanism of ofloxacin electrochemical detection in aqueous solution.” Physical Chemistry Chemical Physics 21(29): 16282-16287.
19. Davis, R. and H. M. Bryson (1994). “Levofloxacin.” Drugs 47(4): 677-700.
20. Blondeau, J. M. (2004). “Fluoroquinolones: mechanism of action, classification, and development of resistance.” Survey of Ophthalmology 49(2): S73-S78.
21. Heifets, L., et al. (2005). “Capreomycin is active against non-replicating M. tuberculosis.” Annals of Clinical Microbiology and Antimicrobials 4(1): 6.
22. Umezawa, H., et al. (1973). “Kanamycin phosphotransferase I: Mechanism of cross resistance between kanamycin and lividomycin.” The Journal of Antibiotics 26(7): 407-411.
23. Alangaden, G. J., et al. (1998). “Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis.” Antimicrobial Agents and Chemotherapy 42(5): 1295-1297.
24. Almeida Da Silva, P. E. and J. C. Palomino (2011). “Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.” Journal of Antimicrobial Chemotherapy 66(7): 1417-1430.
25. Loveday, M., et al. (2018). “MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care.” PloS one 13(4): e0196003.
26. Organization, W. H. (2018). Rapid сommunication: key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB), World Health Organization.
27. Wallach, J. D., et al. (2019). “Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.” Journal of General Internal Medicine 34(4): 492-495.
28. Vasava, M. S., et al. (2019). “Development of new drug-regimens against multidrug-resistant tuberculosis.” Indian Journal of Tuberculosis66(1): 12-19.
29. Jones, J., et al. (2019). “Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases.” BMC Infectious Diseases 19(1): 544.
30. Fujiwara, M., et al. (2018). “Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.” Tuberculosis 108: 186-194.
31. Thompson, A. M., et al. (2017). “Antitubercular nitroimidazoles revisited: synthesis and activity of the authentic 3-nitro isomer of pretomanid.” ACS Medicinal Chemistry Letters 8(12): 1275-1280.
32. Zhanel, G. G., et al. (2015). “Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.” Drugs 75(3): 253-270.
33. Millard, J., et al. (2018). “Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.” Journal of Antimicrobial Chemotherapy73(7): 1755-1762.
34. Seddon, J. A., et al. (2018). “Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done?” The International Journal of Tuberculosis and Lung Disease22(5): S24-S33.
35. Ormerod, L. P. (2005). “Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment.” British medical bulletin 73(1): 17-24.